Figure S1. IC50 of cisplatin in ovarian cancer cells. (A) A2780; (B) CAOV-3; (C) SKOV3; (D) OVCAR5. Cells were seeded in 96-well plate at a density of 3,000 cells/well. Each well was treated with at least five different concentrations of cisplatin for 72 h. Then, an MTT assay was performed to evaluate cell viability, and the IC50 of cisplatin was calculated using GraphPad Prism 7 software. IC50, half-maximal inhibitory concentration.





Figure S2. IC50 of paclitaxel in ovarian cancer cells. (A) A2780; (B) CAOV-3; (C) SKOV3; (D) OVCAR5. Cells were seeded in 96-well plate at a density of 3,000 cells/well. Each well was treated with at least five different concentrations of cisplatin for 72 h. Then, an MTT assay was performed to evaluate cell viability, and the IC50 of cisplatin was calculated using GraphPad Prism 7 software. IC50, half-maximal inhibitory concentration.



Figure S3. IC50 of LLL12 in ovarian cancer cells. (A) A2780; (B) CAOV-3; (C) SKOV3; (D) OVCAR5. Cells were seeded in 96-well plate at a density of 3,000 cells/well. Each well was treated with at least five different concentrations of cisplatin for 72 h. Then, an MTT assay was performed to evaluate cell viability, and the IC50 of cisplatin was calculated using GraphPad Prism 7 software. IC50, half-maximal inhibitory concentration.





IC50: 0.2681

Figure S4. Basal levels of p-STAT3 in ovarian cancer cell lines (A2780, SKOV3, CAOV-3, OVCAR5), assessed by western blotting without drug treatment. p, phosphorylated.

SKOV3	A2780	CAOV-3	OVCAR5	
-	-	-	-	p-STAT3
-	-	-	-	GAPDH